NCT05785819 - A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

December 21, 2024

Study Completion Date

March 31, 2025

Conditions

Thrombocytopenia, ImmuneHeparin Induced Thrombocytopenia

Interventions

DRUG

VLX-1005

VLX-1005, a 12-LOX enzyme inhibitor

DRUG

Placebo

Placebo matching VLX-1005

Trial Locations (14)

19104

NOT_YET_RECRUITING

Universiy of Pennsylvania, Philadelphia

19107

RECRUITING

Thomas Jefferson University, Philadelphia

20007

RECRUITING

Georgetown University, Washington D.C.

20010

RECRUITING

MedStar Washington Hospital Center, Washington D.C.

24014

RECRUITING

Carilion Medical Center, Roanoke

27710

RECRUITING

Duke University, Durham

48109

RECRUITING

University of Michigan, Ann Arbor

53226

RECRUITING

Versiti at Froedtert Hospital, Milwaukee

55905

RECRUITING

Mayo Clinic, Rochester

80045

RECRUITING

University of Colorado, Aurora

94305

RECRUITING

Stanford University, Stanford

97239

RECRUITING

Oregon Health and Science University, Portland

98195

RECRUITING

University of Washington, Seattle

06510

RECRUITING

Yale University, New Haven